mRNAプラットフォーム市場：mRNAタイプ、mRNA分子、用途、適応症、エンドユーザー別-2025-2030年世界予測

mRNAプラットフォーム市場は、2023年に135億2,000万米ドルと評価され、2024年には163億3,000万米ドルに達すると予測され、CAGR 21.44％で成長し、2030年には527億1,000万米ドルに達すると予測されています。

mRNAプラットフォームは、バイオテクノロジーと医薬品における変革的なセグメントであり、主に治療薬とワクチンに応用されるメッセンジャーRNA（mRNA）技術の開発に関与しています。最近のmRNA COVID-19ワクチンの急速な開発と展開によって、その必要性が強調され、ワクチン生産を加速する能力が示されました。ワクチンだけでなく、mRNAの応用範囲は個別化医療、タンパク質代替療法、がんや遺伝性疾患などの病気の治療にも広がっています。最終用途産業には、製薬会社、バイオテクノロジー企業、研究開発や治療開発に従事するヘルスケアプロバイダーが主に含まれます。市場成長の主な原動力は、技術の進歩、アンメット・メディカル・ニーズへの対応能力、バイオテクノロジーへの投資の増加です。新たなビジネスチャンスとしては、再生医療や慢性疾患管理のような従来とは異なる用途でのmRNAの探索や、動物用アプリケーションのようなヒト医療以外でのmRNA使用事例の拡大が挙げられます。このような機会を生かすために、利害関係者は研究パートナーシップや、生産コストを削減し送達ソリューションを強化する技術革新に投資すべきです。

しかし市場は、規制上のハードル、高い開発コスト、mRNAの保管や輸送における物流の複雑さといった課題に直面しており、さらに既存の治療法との競合も生じています。知的財産の障壁やサプライチェーンの脆弱性も大きな制約となっています。それにもかかわらず、特にmRNA製剤の安定性の向上、脂質ナノ粒子のような新規送達システムの開発、大規模製造技術の最適化など、技術革新の可能性は計り知れないです。これらの開発により、疾病管理や治療方法が再定義される可能性があります。市場は非常にダイナミックで、急速な技術シフト、商業的関心の高さ、広範な研究開発活動を特徴としています。持続的な成長のためには、企業は研究を迅速化し、規制プロセスを合理化する共同エコシステムに焦点を当てるべきであり、また新しいmRNAベースのイノベーションの市場投入への道をより円滑にするために政策立案者と関わるべきです。

市場力学：急速に進化するmRNAプラットフォーム市場における主要な市場インサイトの解明

mRNAプラットフォーム市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の健康への備えに対するニーズの高まりに対応するためのワクチン開発の拡大
  • 生物医学分野の進歩に伴うmRNA治療とワクチンの利用可能性の上昇バイオテクノロジーのブレークスルーがmRNA治療とワクチンをスピードと拡張性の新たな高みへ押し上げる
  • mRNA治療とヘルスケアの進歩におけるブレークスルーを促進する資金調達の増加
  • 慢性疾患の増加に伴うmRNA治療へのニーズの高まり
• 市場抑制要因
  • mRNAベースの治療法の普及と拡張性を制限する高い製造コスト
  • 規制上のハードルと長い承認プロセスがmRNAプラットフォームの開発と市場参入を遅らせる
• 市場機会
  • mRNAプラットフォームの統合による精密治療による個別化医療の変革
  • ワクチン以外の治療分野におけるmRNA技術の可能性の拡大
  • 製薬企業との強固な提携によるmRNAベースの治療法の開発と商業化の急速な加速
• 市場の課題
  • mRNAベースの治療を保存・流通させるためのコールドチェーンインフラが限られていること
  • mRNA治療の受容と普及には、安全性と免疫原性に潜在的な懸念があります。

ポーターのファイブフォース：mRNAプラットフォーム市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：mRNAプラットフォーム市場における外部からの影響の把握

外部マクロ環境要因は、mRNAプラットフォーム市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析mRNAプラットフォーム市場における競合情勢の把握

mRNAプラットフォーム市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスmRNAプラットフォーム市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、mRNAプラットフォーム市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨mRNAプラットフォーム市場における成功への道筋を描く

mRNAプラットフォーム市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界の健康対策へのニーズの高まりに応えるため、ワクチン開発が進む
    • バイオメディカル分野の進歩に伴い、mRNA治療とワクチンの利用可能性が高まっている

バイオテクノロジーの進歩により、mRNA治療とワクチンはスピードと拡張性の面で新たな高みに到達

• mRNA治療とヘルスケアの進歩における画期的な進歩を促進するための資金の増額
• 慢性疾患の増加に伴い、mRNA療法の必要性が高まっている
• 抑制要因
  • 生産コストの高さが、mRNAベースの医療の普及と拡張性を制限している
  • 規制上のハードルと長い承認プロセスがmRNAプラットフォームの開発と市場参入を遅らせている
• 機会
  • mRNAプラットフォームの統合により、個別化医療を精密治療に変革
  • ワクチン以外の治療分野におけるmRNA技術の潜在的可能性の拡大
  • 製薬企業との強力な連携により、mRNAベースの治療法の開発と商業化を迅速に加速
• 課題
  • mRNAベースの治療薬の保管と流通のためのコールドチェーンインフラが限られている
  • mRNA療法の受容と広範な使用に対する潜在的な安全性と免疫原性の懸念
• 市場セグメンテーション分析
  • mRNAタイプ：ヌクレオシド修飾mRNAは、免疫応答の有効性と副作用の低減を両立させ、安定性を高める能力がある
  • mRNA分子：正確な標的治療の開発にはモノシストロニックmRNAが必要
  • 応用：新規mRNAプラットフォームによるワクチンの迅速かつ効果的な製造の必要性の拡大
  • 適応症：世界中でがんの罹患率が増加
  • エンドユーザー：mRNAプラットフォームのマーケティングと認可における製薬会社の広範な関与
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 mRNAプラットフォーム市場mRNAタイプ別

• ヌクレオシド修飾mRNA
• 未修飾mRNA

第7章 mRNAプラットフォーム市場mRNA分子別

• モノシストロニックmRNA
• ポリシストロニックmRNA

第8章 mRNAプラットフォーム市場：用途別

• 薬物
• ワクチン

第9章 mRNAプラットフォーム市場適応症別

• 自己免疫疾患
• がん
• 感染症
• 呼吸器疾患

第10章 mRNAプラットフォーム市場：エンドユーザー別

• 病院・クリニック
• 製薬会社
• 調査・学術機関

第11章 南北アメリカのmRNAプラットフォーム市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のmRNAプラットフォーム市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのmRNAプラットフォーム市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • シプラ、新興市場向けmRNAベースの呼吸器治療を加速するためエスリスへの投資を強化
  • アークトゥルス・セラピューティクス、嚢胞性線維症の吸入mRNA治療に関する有望な初期データを欧州会議で発表
  • メルク、mRNAと抗体開発に特化した新研究センターに3億ユーロ以上を投資
  • CureVacとMDアンダーソンが、満たされていない医療ニーズに応えるmRNAベースのがんワクチンの開発で協力
  • VBI Vaccines Inc.がカナダ政府の支援を受けてmRNAワクチン技術を進歩
  • ブラックストーン、モデルナのインフルエンザワクチン開発と商業化を支援するため7億5,000万米ドルを拠出
  • ノボ・ホールディングスが165億米ドルでカタレント社を買収、ノボ・ノルディスク社への戦略的拠点売却を計画
  • TriLink BioTechnologiesと富士フイルム富山化学が提携し、mRNA医薬品の開発と製造の効率化を強化
  • エスリス、ウイルス誘発性喘息に対する革新的な吸入RNA療法の初のヒト試験を開始
  • モデナ社、オーストラリアの新インキュベーターネットワークとワクチン製造施設でmRNA調査を推進
  • ビル＆メリンダ・ゲイツ財団、低所得国向けの低価格mRNAワクチン製造に4,000万米ドルを投資
  • メルクとモデルナ、進行性黒色腫治療の第3相国際試験を開始
  • アプライドDNAサイエンシズ、スピンドルバイオテック買収でmRNA製造を強化、収量向上とコスト削減を目指す
  • センシブル・バイオテクノロジーズとギンゴ・バイオワークスがmRNA生産の革命に向けて戦略的提携を結ぶ
• 戦略分析と提言
  • ファイザー株式会社
  • モデルナ株式会社
  • サノフィSA
  • エトリス株式会社

企業一覧

• Acuitas Therapeutics Inc.
• Arcturus Therapeutics Holdings, Inc.
• Beam Therapeutics Inc.
• BioNTech SE
• Catalent, Inc.
• CureVac N.V.
• Daiichi Sankyo Company, Limited
• Danaher Corporation
• eTheRNA Immunotherapies NV
• Ethris GmbH
• FUJIFILM Holdings Corporation
• Gritstone bio, Inc.
• In-Cell-Art
• Merck KGaA
• Moderna Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Precision BioSciences, Inc.
• Regulus Therapeutics Inc.
• Sangamo Therapeutics, Inc.
• Sanofi SA
• Takara Bio Inc.
• Telesis Bio Inc.
• Thermo Fisher Scientific Inc.
• Tiba Biotech LLC
• TriLink BioTechnologies by Maravai LifeSciences
• Verve Therapeutics, Inc.

LIST OF FIGURES

• FIGURE 1. MRNA PLATFORM MARKET RESEARCH PROCESS
• FIGURE 2. MRNA PLATFORM MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MRNA PLATFORM MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MRNA PLATFORM MARKET DYNAMICS
• TABLE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY UNMODIFIED MRNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY MONOCISTRONIC MRNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY POLYCISTRONIC MRNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MRNA PLATFORM MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. CANADA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 69. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. CHINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. CHINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 74. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. INDIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. INDIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 160. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 161. ITALY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. ITALY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. ITALY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 180. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 181. POLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. POLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. POLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 185. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 186. QATAR MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. QATAR MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. QATAR MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 234. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 235. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023

The mRNA Platform Market was valued at USD 13.52 billion in 2023, expected to reach USD 16.33 billion in 2024, and is projected to grow at a CAGR of 21.44%, to USD 52.71 billion by 2030.

The mRNA platform is a transformative segment within biotechnology and pharmaceuticals, involving the development of messenger RNA (mRNA) technologies for applications primarily in therapeutics and vaccines. Its necessity has been underscored recently by the rapid development and deployment of mRNA COVID-19 vaccines, showcasing its ability to accelerate vaccine production. Beyond vaccines, mRNA's application scope extends to personalized medicine, protein replacement therapies, and treatment of diseases such as cancer and genetic disorders. End-use industries predominantly include pharmaceuticals, biotech firms, and healthcare providers engaged in research and therapeutic development. Market growth is primarily driven by technological advancements, the ability to address unmet medical needs, and increasing investment in biotech. Emerging opportunities include exploring mRNA for non-traditional uses like regenerative medicine and chronic disease management, and expanding mRNA use cases outside of human medicine, such as in veterinary applications. To capitalize on these opportunities, stakeholders should invest in research partnerships and technological innovations that reduce production costs and enhance delivery solutions.

However, the market faces challenges such as regulatory hurdles, high developmental costs, and logistical complexities in mRNA storage and transport, alongside competition from established therapeutic modalities. Intellectual property barriers and supply chain vulnerabilities also pose significant limitations. Nonetheless, the potential for innovation is immense, particularly in improving the stability of mRNA products, developing novel delivery systems (like lipid nanoparticles), and optimizing large-scale manufacturing techniques. These developments could redefine disease management and treatment modalities. The market is highly dynamic, characterized by rapid technological shifts, considerable commercial interest, and extensive R&D activities. For sustained growth, companies should focus on collaborative ecosystems that expedite research and streamline regulatory processes, and they should engage with policy makers to facilitate smoother pathways to market for new mRNA-based innovations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving mRNA Platform Market

The mRNA Platform Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing development of vaccines to meet the rising need for global health preparedness
  • Rising availability of mRNA treatments and vaccines with increasing advancements in the biomedical field Biotech Breakthroughs Propel mRNA Treatments and Vaccines to New Heights in Speed and Scalability
  • Increased funding to fuel breakthroughs in mRNA therapeutics and healthcare advancements
  • Growing need for mRNA therapy with the rising prevalence of chronic diseases
• Market Restraints
  • High production costs limiting the widespread adoption and scalability of mRNA-based medical treatments
  • Regulatory hurdles and lengthy approval processes slowing down mRNA platform development and market entry
• Market Opportunities
  • Integration of mRNA platforms to transform personalized medicine with precision therapies
  • Growing potential of mRNA technology in non-vaccine therapeutic areas
  • Rapid acceleration for the development and commercialization of mRNA-based therapies through robust collaborations with pharmaceutical companies
• Market Challenges
  • Limited cold chain infrastructure for storing and distributing mRNA-based treatments
  • Potential safety and immunogenicity concerns for acceptance and widespread use of mRNA therapies

Porter's Five Forces: A Strategic Tool for Navigating the mRNA Platform Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the mRNA Platform Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the mRNA Platform Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the mRNA Platform Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the mRNA Platform Market

A detailed market share analysis in the mRNA Platform Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the mRNA Platform Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the mRNA Platform Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the mRNA Platform Market

A strategic analysis of the mRNA Platform Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the mRNA Platform Market, highlighting leading vendors and their innovative profiles. These include Acuitas Therapeutics Inc., Arcturus Therapeutics Holdings, Inc., Beam Therapeutics Inc., BioNTech SE, Catalent, Inc., CureVac N.V., Daiichi Sankyo Company, Limited, Danaher Corporation, eTheRNA Immunotherapies NV, Ethris GmbH, FUJIFILM Holdings Corporation, Gritstone bio, Inc., In-Cell-Art, Merck KGaA, Moderna Inc., Novo Nordisk A/S, Pfizer Inc., Precision BioSciences, Inc., Regulus Therapeutics Inc., Sangamo Therapeutics, Inc., Sanofi SA, Takara Bio Inc., Telesis Bio Inc., Thermo Fisher Scientific Inc., Tiba Biotech LLC, TriLink BioTechnologies by Maravai LifeSciences, and Verve Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the mRNA Platform Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on mRNA Type, market is studied across Nucleoside-Modified mRNA and Unmodified mRNA.
• Based on mRNA Molecule, market is studied across Monocistronic mRNA and Polycistronic mRNA.
• Based on Application, market is studied across Drugs and Vaccines.
• Based on Indication, market is studied across Autoimmune Diseases, Cancer, Infectious Diseases, and Respiratory Diseases.
• Based on End-User, market is studied across Hospitals & Clinics, Pharmaceutical Companies, and Research & Academic Institutiions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing development of vaccines to meet the rising need for global health preparedness
    • 5.1.1.2. Rising availability of mRNA treatments and vaccines with increasing advancements in the biomedical field

Biotech Breakthroughs Propel mRNA Treatments and Vaccines to New Heights in Speed and Scalability

• 5.1.1.3. Increased funding to fuel breakthroughs in mRNA therapeutics and healthcare advancements
• 5.1.1.4. Growing need for mRNA therapy with the rising prevalence of chronic diseases
• 5.1.2. Restraints
  • 5.1.2.1. High production costs limiting the widespread adoption and scalability of mRNA-based medical treatments
  • 5.1.2.2. Regulatory hurdles and lengthy approval processes slowing down mRNA platform development and market entry
• 5.1.3. Opportunities
  • 5.1.3.1. Integration of mRNA platforms to transform personalized medicine with precision therapies
  • 5.1.3.2. Growing potential of mRNA technology in non-vaccine therapeutic areas
  • 5.1.3.3. Rapid acceleration for the development and commercialization of mRNA-based therapies through robust collaborations with pharmaceutical companies
• 5.1.4. Challenges
  • 5.1.4.1. Limited cold chain infrastructure for storing and distributing mRNA-based treatments
  • 5.1.4.2. Potential safety and immunogenicity concerns for acceptance and widespread use of mRNA therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability
  • 5.2.2. mRNA Molecule: Requirement of monocistronic mRNA for the development of precise, targeted therapies
  • 5.2.3. Application: Expanding need for quick and effective production of vaccines through novel mRNA platforms
  • 5.2.4. Indication: Increasing prevalence of cancer cases worldwide
  • 5.2.5. End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. mRNA Platform Market, by mRNA Type

• 6.1. Introduction
• 6.2. Nucleoside-Modified mRNA
• 6.3. Unmodified mRNA

7. mRNA Platform Market, by mRNA Molecule

• 7.1. Introduction
• 7.2. Monocistronic mRNA
• 7.3. Polycistronic mRNA

8. mRNA Platform Market, by Application

• 8.1. Introduction
• 8.2. Drugs
• 8.3. Vaccines

9. mRNA Platform Market, by Indication

• 9.1. Introduction
• 9.2. Autoimmune Diseases
• 9.3. Cancer
• 9.4. Infectious Diseases
• 9.5. Respiratory Diseases

10. mRNA Platform Market, by End-User

• 10.1. Introduction
• 10.2. Hospitals & Clinics
• 10.3. Pharmaceutical Companies
• 10.4. Research & Academic Institutiions

11. Americas mRNA Platform Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific mRNA Platform Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa mRNA Platform Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Cipla Boosts Investment in Ethris to Accelerate mRNA-Based Respiratory Therapies for Emerging Markets
  • 14.3.2. Arcturus Therapeutics to Present Promising Early Data on Inhaled mRNA Treatment for Cystic Fibrosis at European Conference
  • 14.3.3. Merck Invests Over Euro 300 Million in New Research Center Focused on mRNA and Antibody Development
  • 14.3.4. CureVac and MD Anderson Collaborate on mRNA-Based Cancer Vaccines for Unmet Medical Needs
  • 14.3.5. VBI Vaccines Inc.'s Advancement in mRNA Vaccine Technology with Government of Canada Support
  • 14.3.6. Blackstone Commits USD 750 Million to Support Moderna's Influenza Vaccine Development and Commercialization
  • 14.3.7. Novo Holdings Acquires Catalent for USD 16.5 Billion, Plans Strategic Site Sales to Novo Nordisk
  • 14.3.8. TriLink BioTechnologies and FUJIFILM Toyama Chemical Forge Partnership to Enhance mRNA Drug Development and Manufacturing Efficiency
  • 14.3.9. Ethris Launches First Human Trial of Innovative Inhaled RNA Therapy for Virus-Induced Asthma
  • 14.3.10. Moderna Inc. Advances mRNA Research with New Australian Incubator Network and Vaccine Manufacturing Facility
  • 14.3.11. Bill & Melinda Gates Foundation Invests USD 40 Million in Affordable mRNA Vaccine Manufacturing for Low-Income Nations"
  • 14.3.12. Merck and Moderna Launch Global Phase 3 Trial for Advanced Melanoma Therapy
  • 14.3.13. Applied DNA Sciences Enhances mRNA Manufacturing with Spindle Biotech Acquisition, Aims to Improve Yields and Reduce Costs
  • 14.3.14. Sensible Biotechnologies and Ginkgo Bioworks Forge Strategic Alliance for Revolutionizing mRNA Production
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Pfizer Inc.
  • 14.4.2. Moderna, Inc.
  • 14.4.3. Sanofi SA
  • 14.4.4. Ethris GmbH

Companies Mentioned

• 1. Acuitas Therapeutics Inc.
• 2. Arcturus Therapeutics Holdings, Inc.
• 3. Beam Therapeutics Inc.
• 4. BioNTech SE
• 5. Catalent, Inc.
• 6. CureVac N.V.
• 7. Daiichi Sankyo Company, Limited
• 8. Danaher Corporation
• 9. eTheRNA Immunotherapies NV
• 10. Ethris GmbH
• 11. FUJIFILM Holdings Corporation
• 12. Gritstone bio, Inc.
• 13. In-Cell-Art
• 14. Merck KGaA
• 15. Moderna Inc.
• 16. Novo Nordisk A/S
• 17. Pfizer Inc.
• 18. Precision BioSciences, Inc.
• 19. Regulus Therapeutics Inc.
• 20. Sangamo Therapeutics, Inc.
• 21. Sanofi SA
• 22. Takara Bio Inc.
• 23. Telesis Bio Inc.
• 24. Thermo Fisher Scientific Inc.
• 25. Tiba Biotech LLC
• 26. TriLink BioTechnologies by Maravai LifeSciences
• 27. Verve Therapeutics, Inc.